Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new trial starting in January 2016 will compare different medical devices used in hip fracture surgery, aiming to improve the efficiency of these operations.

Xavier Griffin, Consultant Trauma Surgeon, Oxford University Hospitals Foundation Trust and Chief Investigator on the trial says: "Fractures of the hip are the most devastating of the musculoskeletal fragility injuries that we see in orthopaedic trauma practice in the UK. They alone make up 1.4% of health and social care costs and herald a step change in patients mobility and independence.

Interventions which can help us better treat these injuries are crucial to improving the health of our patients. We are excited about our new collaboration with X-Bolt Orthopaedics which will allow us to investigate this implant for fixation of hip fractures which may yield better outcomes for these patients."

Fractures of the hip are the most devastating of the musculoskeletal fragility injuries that we see in orthopaedic trauma practice in the UK - Xavier Griffin, Consultant Trauma Surgeon and Chief Investigator

Hip fractures account for an estimated £1.1 billion in hospital costs annually, with failed hip fracture fixations and re-operations accounting for approximately £30m; the impact on the patients and loss of independence are immeasurable.

The 1000 patient, multicentre, randomised, controlled trial World Hip Trauma Evaluation Four (WHiTE Four) will compare two different treatments for extracapsular hip fractures - sliding hip screw fixation (SHS) and X-Bolt Dynamic Hip Plating system - following a successful smaller clinical trial that showed a zero re-operation risk for the X-Bolt System.

SHS is well established in the treatment of extracapsular fractures. However, in some hip fractures there is deficient bone to share load with the fixation device leading to failure of the fixation, often leading to more surgery and poor outcomes.

The new X-Bolt Dynamic Hip plating system builds on the successful design features of the SHS but differs in the nature of the fixation in the head. The system was designed to significantly improve the effectiveness of current surgical treatment and reduce the requirement for very costly and often devastating repeat surgery.

Both operations carry substantial and similar general risks due to the nature of the surgery and the typical frailty of the patient population. Treatment of this type of fracture remains controversial but the potential advantages of improved fixation in the femoral head may reduce failure rates with this novel device compared to the current gold standard.

WHITE-4_logo

Similar stories

Yoshi Itoh wins the International Dupuytren Award 2022

Yoshi Itoh, Associate Professor and Principal Investigator Cell Migration Group at the Kennedy Institute has been awarded the International Dupuytren Award 2022.

Taking a break from immune-suppressing medicines doubles the antibody response to COVID-19 booster vaccination

The Oxford Clinical Trials Research Unit (OCTRU) at NDORMS played a key role in the VROOM study which found that pausing immune-suppressing medicines such as methotrexate can increase the response to COVID-19 booster jabs.

Ten Years of Athena Swan in the Medical Sciences Division

2022 marks ten years since the first Athena Swan Bronze applications from the Medical Sciences Division. Ten years later, and all 16 departments in the Division have achieved a Silver Award. We look at NDORMS’ Athena Swan journey.

NDORMS researchers awarded Associate Professor title

The University of Oxford has awarded the title of Associate Professor to Adam Cribbs and Luke Jostins.

Oxford's largest ever study into varicose veins shows need for surgery is linked to genetics

A new international study by Oxford researchers published in Nature Communications, establishes for the first time a critical genetic risk score to predict the likelihood of patients suffering with varicose veins to require surgery, as well as pointing the way towards potential new therapies.

Reflecting on the role of Clinical Director of Trauma and Orthopaedics

In 2021 Professor Andrew Price was appointed Clinical Director of Trauma and Orthopaedics at the Oxford University Hospitals NHS Foundation Trust. After 9 months in post, we find out what the challenges are and what he’s been able to bring to the role.